Trial Profile
The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary) ; Prednisolone
- Indications Asthma; Chronic obstructive pulmonary disease; Inflammation
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 Sep 2012 New trial record
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.